Completed
Effect of Perimenstrual Ovarian Steroid Supplementation on Perimenstrual Suicidality
Ovarian Hormone Withdrawal and Suicide Risk: An Experimental Approach
- Status
- Completed
- Registry ID
- NCT03720847
- Type
- Interventional (tests a treatment)
- Phase
- Phase 4
- Conditions
- Suicidal Ideation
- What is tested
- Estradiol Transdermal Patch 0.1 mg/24 hrs (drug); Oral Micronized Progesterone (drug); Inactive Clear Patch (drug); Placebo capsule (drug)
- Sponsor
- University of North Carolina, Chapel Hill
- Where
- United States
- Participants
- 30
- Start
- 2016-12-31
- Completion
- 2017-11
- Last update
- 2019-02-04
- Results posted
- Yes
About the study
This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) natural perimenstrual withdrawal from estradiol and progesterone (during placebo), (2) perimenstrual stabilization of estradiol and progesterone using transdermal estradiol and oral micronized progesterone.
Summary from ClinicalTrials.gov.